BLASUBCUTANEOUS LYOPHILIZED POWERINJECTABLE1 Generic Approved
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
NUCALA (mepolizumab) by GSK is interleukin-5 antagonists [moa]. Approved for interleukin-5 antagonist [epc]. First approved in 2015.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUCALA (mepolizumab) is a monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine in eosinophil development and activation. It is indicated for severe eosinophilic asthma and other eosinophil-mediated conditions. The drug works by binding to IL-5, reducing circulating eosinophils and their tissue infiltration.
$261MPart D
PeakNUCALA is at peak commercial maturity with substantial Medicare utilization, indicating stable team structures and predictable revenue, though moderate competitive pressure may limit expansion.
Mechanism of Action
Interleukin-5 Antagonists
Pharmacologic Class:
Interleukin-5 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
Started Sep 2025
591 enrolled
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Started Mar 2024
336 enrolled
Asthma
Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma
Started Feb 2024
57 enrolled
Chronic Rhinosinusitis With Nasal PolypsAsthma
Immunological Basis for Mepolizumab Activity in COPD
Started Apr 2023
30 enrolled
COPD
Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices
Started Mar 2023
20 enrolled
Asthma
Worked on NUCALA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.